Loading...
01/10 23:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session indicate strong financial metrics with raised guidance across revenue, EBITDA, EPS, and free cash flow. The Kinectrics acquisition and government/commercial operations show promising growth. Despite some risks, such as lower initial margins and delayed Project Pele delivery, the market strategy with SMRs and medical segment growth is optimistic. The positive sentiment is further supported by the strategic partnerships and opportunities in nuclear energy. Overall, the outlook suggests a positive stock price movement, likely in the 2% to 8% range.
Revenue Third quarter revenue was $866 million, up 29% year-over-year, driven by both Government and Commercial Operations. Excluding contributions from acquisitions, organic revenue was up 12%. The increase was attributed to strong growth in both segments.
Adjusted EBITDA Adjusted EBITDA was $151 million, up 19% year-over-year, driven by robust double-digit growth in Commercial Operations, a modest increase in Government Operations, and lower corporate expense.
Adjusted Earnings Per Share (EPS) Adjusted EPS was $1, up 20% year-over-year, driven by strong operating performance. Nonoperating items were neutral on a net basis.
Free Cash Flow Third quarter free cash flow was $95 million, driven by solid earnings performance and timing of cash receipts from major awards.
Government Operations Revenue Revenue was up 10% year-over-year, driven by Naval Propulsion, Long Lead Material Procurement, Special Materials, and a roughly 3% contribution from the AOT acquisition. This was partially offset by a decline in microreactor volume.
Government Operations Adjusted EBITDA Adjusted EBITDA of $118 million was up modestly compared to last year, resulting in an adjusted EBITDA margin of 19.2%. The modest increase was due to growth in revenue and operational performance.
Commercial Operations Revenue Revenue was up 122% year-over-year, driven by contribution from the Kinectrics acquisition. Organic revenue growth was 38%, driven by strong year-over-year growth in the Commercial Power business and double-digit growth in Medical.
Commercial Operations Adjusted EBITDA Adjusted EBITDA in the segment was $36 million, up 163% year-over-year. This resulted in an adjusted EBITDA margin of 14.2%, driven by solid operational performance and a more favorable mix compared to recent periods.
Backlog Total backlog was $7.4 billion, up 23% from last quarter and up 119% year-over-year. The increase was driven by large multiyear national security contracts for the production of defense fuels and high-purity depleted uranium in the Special Materials line of business.
Microreactors and advanced nuclear technologies: Manufacturing the reactor core for Pele, on track for delivery in 2027. Army announced the Janus program to deploy a nuclear reactor by 2028, with BWXT's qualification as a differentiator.
TRISO nuclear fuel production: Collaboration with Kairos Power to optimize production. Producing TRISO fuel for Project Pele and other customers, with potential for larger commercial market entry.
Special Materials business line: Awarded $1.5 billion defense fuels contract for domestic uranium enrichment and $1.6 billion contract for high-purity depleted uranium supply. Building facilities in Tennessee for these projects.
Commercial Power and SMR sector: Strong demand and expanding opportunities. Signed contract with Rolls-Royce for SMR steam generators and MOU for manufacturing phase. Tracking opportunities in international CANDU life extensions and other large-scale projects.
Operational excellence: Leveraging AI and advanced manufacturing for quality control and workflow efficiencies in Naval Propulsion business.
Capacity expansion: Investing in growth initiatives, including commercial nuclear capacity expansion and smaller government projects.
Strategic petroleum reserve M&O contract: Transitioning to operational control of Canadian Nuclear Laboratories by year-end.
Kinectrics acquisition: Driving revenue growth in commercial nuclear power and medical isotopes, with expanded production capacity for cancer radiotherapy isotopes.
Government Operations: Challenges in meeting delivery commitments for submarine and aircraft carrier programs, requiring intense focus on operational excellence and leveraging advanced technologies to improve productivity and margins.
Special Materials Business: Execution risks associated with long-term projects like the $1.5 billion defense fuels contract and the $1.6 billion high-purity depleted uranium contract, including building new manufacturing facilities and ensuring timely delivery.
Commercial Operations: Pressure on adjusted EBITDA margins due to timing of recovery of higher material procurement costs, particularly in the first half of the year.
Capital Expenditures: Increased capital expenditures (6% of sales) for growth initiatives, including capacity expansion for commercial nuclear and government business, which could strain cash flow.
International Earnings: Higher tax rates expected in 2026 due to a greater percentage of international earnings following the Kinectrics acquisition.
Free Cash Flow: Near-term working capital investments related to significant business growth may lead to flat or slightly higher free cash flow in 2026.
Special Materials Portfolio: Below-average margins in the initial phases of customer-funded CapEx projects for defense fuels and high-purity depleted uranium programs.
2026 Financial Outlook: BWXT anticipates another year of record financial results in 2026, with low double-digit to low teens adjusted EBITDA growth and high single-digit to low double-digit adjusted earnings per share growth. Free cash flow is expected to be flat to slightly higher due to near-term working capital investments.
Government Operations Revenue Growth: Revenue in this segment is expected to grow in the mid-teens in 2026, driven by growth in Special Materials, Naval Propulsion, and microreactors. Over half of the growth will come from the defense fuels program and high-purity depleted uranium (HPDU) projects.
Commercial Operations Revenue Growth: Commercial Operations is expected to achieve low double-digit organic revenue growth in 2026, with additional contributions from the Kinectrics acquisition. Adjusted EBITDA growth is expected to outperform revenue growth due to favorable mix and solid execution.
Capital Expenditures: Capital expenditures are expected to remain at 5.5% to 6% of sales in 2026, supporting long-term growth initiatives.
Special Materials Projects: BWXT is focused on long-term projects, including a $1.5 billion defense fuels contract and a $1.6 billion contract for high-purity depleted uranium. These projects involve building new manufacturing facilities and are expected to drive significant revenue growth.
Microreactors and Advanced Nuclear Technologies: The reactor core for Project Pele is on track for delivery in 2027. The Army's Janus program, aiming to deploy a nuclear reactor by September 2028, presents additional opportunities for BWXT.
Medical Isotopes and Therapeutics: BWXT Medical expects continued revenue growth in 2026, driven by PET and diagnostic product lines, as well as increasing therapeutic isotope sales for clinical trials. The company is also progressing on tech-99 development for an FDA submission.
Commercial Power and SMR Sector: Demand in the commercial power sector remains strong, with opportunities in CANDU life extensions, new builds, and SMR projects. BWXT recently signed a contract with Rolls-Royce for SMR steam generator design and manufacturing.
The selected topic was not discussed during the call.
The earnings call summary and Q&A session indicate strong financial metrics with raised guidance across revenue, EBITDA, EPS, and free cash flow. The Kinectrics acquisition and government/commercial operations show promising growth. Despite some risks, such as lower initial margins and delayed Project Pele delivery, the market strategy with SMRs and medical segment growth is optimistic. The positive sentiment is further supported by the strategic partnerships and opportunities in nuclear energy. Overall, the outlook suggests a positive stock price movement, likely in the 2% to 8% range.
The earnings call summary shows strong strategic developments, including backlog growth, new contracts, and expansion plans, indicating positive future prospects. The Q&A section reveals proactive measures addressing bottlenecks and strategic partnerships, with analysts showing interest in nuclear and microreactor markets. Despite some uncertainties, the guidance remains optimistic, with a focus on revenue growth and margin expectations. The overall sentiment leans towards positive, suggesting a stock price increase over the next two weeks.
The earnings call summary shows strong financial performance with revenue, EBITDA, and EPS all up significantly year-over-year. Despite some margin pressure due to zirconium costs, management expects recovery in the second half. The Q&A indicates optimism about government contracts and nuclear projects, with strong support from the administration. The backlog and strategic acquisitions further enhance growth prospects. While there is some uncertainty in the ANPI program, overall sentiment remains positive, suggesting a likely stock price increase in the short term.
The earnings call summary presents a mixed picture. The basic financial performance and expenses are impacted by material costs, but there's optimism about future recovery. Product development shows progress but faces delays. Market strategy is promising with potential government contracts. Shareholder returns weren't specifically addressed. The Q&A reveals uncertainties in some programs and materials issues, balancing the positive aspects. Overall, the sentiment remains neutral due to these mixed signals and the lack of a clear positive catalyst.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
